BI 1820237 + Placebo for BI 1820237 + Placebo for BI 456906 + Survodutide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Apr 2024: Trial registered, NCT06352424
  2. 30 Apr 2024: Trial started, NCT06352424

The trials

NCT06352424: A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

State
Completed
Phase
Phase 1
People
23 taking part
Started
30 Apr 2024
Primary completion
24 Feb 2025
Arms
A-B-C-D, B-D-A-C, C-A-D-B, D-C-B-A
Results
None posted
  1. 8 Apr 2024: Trial registered
  2. 30 Apr 2024: Trial started
  3. 24 Feb 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.